DOR BioPharma, Inc.: DOR BioPharma Reports Third Quarter Financial Results, Reviews Recent Achievements
15th Nov 2006, 00:33 GMT
MIAMI, FL (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") today announced financial results for the third quarter ended September 30, 2006.
DOR BioPharma, Inc.: DOR BioPharma Reports Third Quarter Financial Results, Reviews Recent Achievements related news:
- Adherex Reports Third Quarter 2006 Financial Results — ArriveNet : Press Releases
- Jaclyn Reports First Quarter Financial Results; Announces Developments Concerning Purchase Option on West New York Facility — ArriveNet : Press Releases
- Catalytica Energy Systems, Inc.: Catalytica Energy Systems Reports Third Quarter Financial Results — Market Wire - Energy and Utilities
- Novacea Reports Third Quarter 2006 Financial Results — ArriveNet : Press Releases
- Ambrilia Biopharma Inc.: Ambrilia Announces Third Quarter 2006 Results and Provides Update on Lead Development Programs — Market Wire - Pharmaceuticals and Biotech
- Varsity Group Inc. Reports Third Quarter Results — ArriveNet : Business
- Novacea: Novacea Reports Third Quarter 2006 Financial Results — Market Wire - Earnings Reports
- SpaceDev Reports Third Quarter Fiscal 2006 Results — ArriveNet : Travel
- Jaclyn, Inc.: Jaclyn Reports First Quarter Financial Results; Announces Developments Concerning Purchase Option on West New York Facility — Market Wire - Retail
- Mindready Solutions Reports Third Quarter 2006 Results — ArriveNet : Government
Latest news from Market Wire - Medical and Healthcare:
- slp3D: ORLive Presents: Minimally Invasive Aortic Valve Replacement Surgery -- Increasingly Popular Procedure to Correct Heart Function
- Precise Biometrics AB: Extraordinary general meeting of Precise Biometrics AB approves of new share issue with preferential rights for shareholders of approximately SEK 85 million
- Lenstec, Inc.: Lenstec Receives FDA Clearance to Begin Clinical Trial of Softec HD IOL
- Takeda Pharmaceuticals North America: New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
- Dairy Fresh Farms Inc.: Dairy Fresh Farms Announces It Has Signed a Licensing Deal With NutriOne for the Canadian Market
- OTSP: Study to Be Published in JAMA: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT)
- Vue Technology: Vue Technology Introduces First UHF Solution for Item-Level Visibility in the Retail Pharmacy; New RFID Solution Tracks Liquids, Pill Bottles, Blister Packs and Gels
- Union Dental Holdings, Inc.: Union Dental Signs Contract to Provide Dental Network for United Association of Plumbers and Pipefitters
- MEDSEEK: MEDSEEK, SelfCareNet, & Primetime Medical Partner to Deliver Integrated Consumer-Centric Solution
- Ridgecrest Healthcare Group, Inc.: Ridgecrest Healthcare Group to Acquire NOBO List